Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today that James Drew Veltmeyer, M.D., has been appointed to the Company’s Scientific Advisory Board.
Dr. James Veltmeyer, MD is a board certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors. Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.
“It is our great pleasure to welcome Dr. James Veltmeyer to our Scientific Advisory Board. Dr. Veltmeyer in coming to this country at age eleven after suffering homelessness and hardship in his South American country of birth, Dr. Veltmeyer has achieved phenomenal success because he had an opportunity to come to the United States and enter our educational system where he pursued the field of medicine. We are deeply honored to have Dr. Veltmeyer on our distinguished scientific team,” said Timothy Dixon, President and CEO.
“I am enthusiastic to work besides the team assembled by Mr. Dixon in advancing the commercialization of the patented pterostilbene-based immunotherapeutic products for treatment of cancer and other medical conditions,” said Dr. Veltmeyer.
“Dr. Veltmeyer possesses unparalleled insight in the practice of medicine. Combined with his unique curiosity and problem solving mindset, we are very eager to begin our collaborations with Dr. Veltmeyer, which we believe will translate into new treatments for patients,” said Dr. Thomas Ichim, Board Member of TSOI and CEO of Emvolio, Inc.
Do you like my commentaries and podcasts? Help me get the message out to a wider audience by making a donation today. Thank you for your support!